Markets:

Overview

News

Currencies

International

Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

3.415 +0.135 (+4.12%)

Streaming Delayed Price Updated: 1:09 PM EDT, Jul 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 21, 2025

Via Benzinga

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

March 27, 2025

From Alvotech

Via GlobeNewswire

Alvotech Reports Record Results for 2024 and Provides Business Update

March 26, 2025

From Alvotech

Via GlobeNewswire

Earnings Scheduled For November 13, 2024 ↗

November 13, 2024

Via Benzinga

Alvotech's Earnings Outlook ↗

November 12, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 26, 2025

Via Benzinga

Earnings Scheduled For March 26, 2025 ↗

March 26, 2025

Via Benzinga

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

March 26, 2025

From Alvotech

Via GlobeNewswire

Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal ↗

March 20, 2025

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities and expanding into Sweden.

Via Benzinga

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

March 20, 2025

From Alvotech

Via GlobeNewswire

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

March 18, 2025

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

March 18, 2025

From Alvotech

Via GlobeNewswire

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

March 07, 2025

From Alvotech

Via GlobeNewswire

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

February 21, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

February 18, 2025

From Teva Pharmaceutical Industries Ltd; Alvotech

Via GlobeNewswire

Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket ↗

January 28, 2025

Via Benzinga

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

January 27, 2025

From Alvotech

Via GlobeNewswire

JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 17, 2025

Via Benzinga

Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket ↗

January 17, 2025

Via Benzinga

Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 15, 2025

Via Benzinga

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

December 23, 2024

From Alvotech

Via GlobeNewswire

Alvotech Reports Financial Results for the First Nine Months of 2024

November 13, 2024

From Alvotech

Via GlobeNewswire

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

November 07, 2024

From Alvotech

Via GlobeNewswire

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

November 04, 2024

From Alvotech

Via GlobeNewswire

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

October 30, 2024

From Alvotech

Via GlobeNewswire

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

October 25, 2024

From Alvotech

Via GlobeNewswire

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

October 10, 2024

From Alvotech

Via GlobeNewswire

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

September 25, 2024

From Alvotech

Via GlobeNewswire

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars ↗

September 11, 2024

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.

Via Benzinga

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 26, 2024

From Alvotech

Via GlobeNewswire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.